FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2284643705> ?p ?o ?g. }

• W2284643705 abstract "Abstract Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson’s disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T 4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists." @default.
• W2284643705 created "2016-06-24" @default.
• W2284643705 creator A5004223415 @default.
• W2284643705 creator A5013150457 @default.
• W2284643705 creator A5020895462 @default.
• W2284643705 creator A5022777211 @default.
• W2284643705 creator A5025858582 @default.
• W2284643705 creator A5041250326 @default.
• W2284643705 creator A5042219120 @default.
• W2284643705 creator A5048849343 @default.
• W2284643705 creator A5050320694 @default.
• W2284643705 creator A5050392185 @default.
• W2284643705 creator A5051822191 @default.
• W2284643705 creator A5067651759 @default.
• W2284643705 creator A5073284191 @default.
• W2284643705 creator A5083494051 @default.
• W2284643705 creator A5088109143 @default.
• W2284643705 creator A5091692002 @default.
• W2284643705 date "2016-02-23" @default.
• W2284643705 modified "2023-10-18" @default.
• W2284643705 title "Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity" @default.
• W2284643705 cites W1579462161 @default.
• W2284643705 cites W1794576275 @default.
• W2284643705 cites W189796632 @default.
• W2284643705 cites W1968632585 @default.
• W2284643705 cites W1969264932 @default.
• W2284643705 cites W1970157807 @default.
• W2284643705 cites W1972000849 @default.
• W2284643705 cites W1975692580 @default.
• W2284643705 cites W1977124092 @default.
• W2284643705 cites W1979219069 @default.
• W2284643705 cites W1979704176 @default.
• W2284643705 cites W1980106300 @default.
• W2284643705 cites W1983287291 @default.
• W2284643705 cites W1984035915 @default.
• W2284643705 cites W1987063515 @default.
• W2284643705 cites W1990580716 @default.
• W2284643705 cites W1993241304 @default.
• W2284643705 cites W1995860001 @default.
• W2284643705 cites W1997585395 @default.
• W2284643705 cites W2002615785 @default.
• W2284643705 cites W2011246655 @default.
• W2284643705 cites W2015219413 @default.
• W2284643705 cites W2015654033 @default.
• W2284643705 cites W2018146982 @default.
• W2284643705 cites W2019261756 @default.
• W2284643705 cites W2022945618 @default.
• W2284643705 cites W2023014768 @default.
• W2284643705 cites W2025112049 @default.
• W2284643705 cites W2027142021 @default.
• W2284643705 cites W2032556980 @default.
• W2284643705 cites W2038935930 @default.
• W2284643705 cites W2052724974 @default.
• W2284643705 cites W2058078504 @default.
• W2284643705 cites W2064278776 @default.
• W2284643705 cites W2065835715 @default.
• W2284643705 cites W2070555511 @default.
• W2284643705 cites W2071351026 @default.
• W2284643705 cites W2080298680 @default.
• W2284643705 cites W2081954759 @default.
• W2284643705 cites W2090415718 @default.
• W2284643705 cites W2090907772 @default.
• W2284643705 cites W2093861673 @default.
• W2284643705 cites W2094309420 @default.
• W2284643705 cites W2094587801 @default.
• W2284643705 cites W2098318720 @default.
• W2284643705 cites W2102465370 @default.
• W2284643705 cites W2113689256 @default.
• W2284643705 cites W2122530165 @default.
• W2284643705 cites W2142822529 @default.
• W2284643705 cites W2144688054 @default.
• W2284643705 cites W2148373528 @default.
• W2284643705 cites W2148937629 @default.
• W2284643705 cites W2154119752 @default.
• W2284643705 cites W2158907165 @default.
• W2284643705 cites W2160950772 @default.
• W2284643705 cites W2161532460 @default.
• W2284643705 cites W2162710350 @default.
• W2284643705 cites W2165186407 @default.
• W2284643705 cites W2166550586 @default.
• W2284643705 cites W2169280166 @default.
• W2284643705 cites W2173185813 @default.
• W2284643705 cites W2312608249 @default.
• W2284643705 cites W3120747399 @default.
• W2284643705 cites W3143250482 @default.
• W2284643705 cites W4322701596 @default.
• W2284643705 cites W6312680 @default.
• W2284643705 doi "https://doi.org/10.1038/ncomms10787" @default.
• W2284643705 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4766415" @default.
• W2284643705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26902880" @default.
• W2284643705 hasPublicationYear "2016" @default.
• W2284643705 type Work @default.
• W2284643705 sameAs 2284643705 @default.
• W2284643705 citedByCount "126" @default.
• W2284643705 countsByYear W22846437052016 @default.
• W2284643705 countsByYear W22846437052017 @default.
• W2284643705 countsByYear W22846437052018 @default.
• W2284643705 countsByYear W22846437052019 @default.
• W2284643705 countsByYear W22846437052020 @default.
• W2284643705 countsByYear W22846437052021 @default.

• next